Glo-Vision Medicaments Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 22-12-2024
- Paid Up Capital ₹ 1.65 M
as on 22-12-2024
- Company Age 21 Year, 7 Months
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 10.37 Cr
as on 22-12-2024
- Satisfied Charges ₹ 2.50 M
as on 22-12-2024
- Revenue -99.69%
(FY 2017)
- Profit 29.83%
(FY 2017)
- Ebitda 84.10%
(FY 2017)
- Net Worth -0.76%
(FY 2017)
- Total Assets -0.16%
(FY 2017)
About Glo-Vision Medicaments
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 1.65 M.
The company currently has active open charges totaling ₹10.37 Cr. The company has closed loans amounting to ₹2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Manoj Raka, Parasmal Raka, and Dinesh Raka serve as directors at the Company.
- CIN/LLPIN
U24230MH2003PLC140778
- Company No.
140778
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
06 Jun 2003
- Date of AGM
26 Sep 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Glo-Vision Medicaments?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Raka  | Additional Director | 31-Mar-2009 | Current |
| Parasmal Raka | Additional Director | 06-Jul-2010 | Current |
| Dinesh Raka | Director | 06-Jun-2003 | Current |
Financial Performance of Glo-Vision Medicaments.
Glo-Vision Medicaments Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 99.69% decrease. The company also saw a substantial improvement in profitability, with a 29.83% increase in profit. The company's net worth dipped by a decrease of 0.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glo-Vision Medicaments?
In 2017, Glo-Vision Medicaments had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 05 Oct 2012 | ₹4.50 Cr | Open |
Bank Of Baroda Creation Date: 09 May 2012 | ₹1.17 M | Open |
Bank Of Baroda Creation Date: 27 Jul 2011 | ₹4.50 Cr | Open |
How Many Employees Work at Glo-Vision Medicaments?
Unlock and access historical data on people associated with Glo-Vision Medicaments, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glo-Vision Medicaments, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glo-Vision Medicaments's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
